Janus Henderson Group PLC Has $35.06 Million Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Janus Henderson Group PLC trimmed its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 35.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,897,340 shares of the biotechnology company's stock after selling 1,021,738 shares during the period. Janus Henderson Group PLC owned approximately 2.08% of Rocket Pharmaceuticals worth $35,055,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Rocket Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company's stock worth $61,000 after acquiring an additional 582 shares in the last quarter. Dana Investment Advisors Inc. lifted its stake in Rocket Pharmaceuticals by 4.4% during the second quarter. Dana Investment Advisors Inc. now owns 13,847 shares of the biotechnology company's stock worth $298,000 after purchasing an additional 586 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Rocket Pharmaceuticals by 31.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company's stock valued at $68,000 after purchasing an additional 764 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Rocket Pharmaceuticals by 1.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,633 shares of the biotechnology company's stock valued at $2,210,000 after purchasing an additional 1,561 shares during the last quarter. Finally, Pier 88 Investment Partners LLC raised its holdings in shares of Rocket Pharmaceuticals by 5.1% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 32,490 shares of the biotechnology company's stock worth $600,000 after buying an additional 1,590 shares in the last quarter. 98.39% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 11,091 shares of the firm's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $13.05, for a total transaction of $144,737.55. Following the completion of the transaction, the chief executive officer now owns 707,328 shares in the company, valued at approximately $9,230,630.40. This trade represents a 1.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 13,490 shares of company stock valued at $176,045. 28.50% of the stock is currently owned by company insiders.

Rocket Pharmaceuticals Trading Up 4.3 %

Shares of Rocket Pharmaceuticals stock traded up $0.57 during trading on Friday, hitting $13.89. The company's stock had a trading volume of 662,907 shares, compared to its average volume of 971,935. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -5.05 and a beta of 1.01. Rocket Pharmaceuticals, Inc. has a 52 week low of $12.62 and a 52 week high of $32.53. The stock has a 50-day moving average price of $16.02 and a two-hundred day moving average price of $19.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $39.00 price objective on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $52.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price objective on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Scotiabank initiated coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $50.00 target price on the stock. Finally, Chardan Capital reiterated a "buy" rating and issued a $62.00 price target on shares of Rocket Pharmaceuticals in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $51.00.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.